JP2023534437A5 - - Google Patents

Info

Publication number
JP2023534437A5
JP2023534437A5 JP2023501559A JP2023501559A JP2023534437A5 JP 2023534437 A5 JP2023534437 A5 JP 2023534437A5 JP 2023501559 A JP2023501559 A JP 2023501559A JP 2023501559 A JP2023501559 A JP 2023501559A JP 2023534437 A5 JP2023534437 A5 JP 2023534437A5
Authority
JP
Japan
Prior art keywords
group
compound according
glycine
antibody
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041304 external-priority patent/WO2022015656A1/en
Publication of JP2023534437A publication Critical patent/JP2023534437A/ja
Priority to JP2023214174A priority Critical patent/JP7776485B2/ja
Publication of JP2023534437A5 publication Critical patent/JP2023534437A5/ja
Pending legal-status Critical Current

Links

JP2023501559A 2020-07-13 2021-07-12 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 Pending JP2023534437A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023214174A JP7776485B2 (ja) 2020-07-13 2023-12-19 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051172P 2020-07-13 2020-07-13
US63/051,172 2020-07-13
US202163154531P 2021-02-26 2021-02-26
US63/154,531 2021-02-26
PCT/US2021/041304 WO2022015656A1 (en) 2020-07-13 2021-07-12 Camptothecin analogs conjugated to a glutamine residue in a protein, and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023214174A Division JP7776485B2 (ja) 2020-07-13 2023-12-19 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用

Publications (2)

Publication Number Publication Date
JP2023534437A JP2023534437A (ja) 2023-08-09
JP2023534437A5 true JP2023534437A5 (enExample) 2024-07-19

Family

ID=77168491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501559A Pending JP2023534437A (ja) 2020-07-13 2021-07-12 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用
JP2023214174A Active JP7776485B2 (ja) 2020-07-13 2023-12-19 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023214174A Active JP7776485B2 (ja) 2020-07-13 2023-12-19 タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用

Country Status (14)

Country Link
US (2) US12605459B2 (enExample)
EP (2) EP4406608A3 (enExample)
JP (2) JP2023534437A (enExample)
KR (2) KR20230038738A (enExample)
CN (2) CN116390771A (enExample)
AU (2) AU2021308190A1 (enExample)
BR (1) BR112023000489A2 (enExample)
CA (1) CA3183184A1 (enExample)
CL (1) CL2023000098A1 (enExample)
CO (1) CO2023001402A2 (enExample)
IL (2) IL299153A (enExample)
MA (1) MA71650A (enExample)
MX (2) MX2023000544A (enExample)
WO (1) WO2022015656A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093439A1 (en) * 2020-01-22 2022-11-30 MedImmune Limited Compounds and conjugates thereof
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
JP2023551355A (ja) * 2020-09-30 2023-12-08 デュアリティ バイオロジクス(スーチョウ)カンパニー,リミティド 抗腫瘍化合物並びにその調製方法及び使用
CA3241734A1 (en) * 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
EP4471005A4 (en) * 2022-01-24 2025-11-19 Beijing Chempion Biotechnology Co Ltd CONJUGATED AND ITS USE
WO2023172968A1 (en) * 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药(苏州)有限公司 一种喜树碱衍生物,基于其的抗体-药物偶联物和药物组合物,及其应用
WO2024008102A1 (en) * 2022-07-05 2024-01-11 Wuxi Xdc (Shanghai) Co., Ltd. Linker for conjugation
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
KR20250069963A (ko) * 2022-09-30 2025-05-20 베이진 스위찰랜드 게엠베하 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도
KR20250116795A (ko) 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
WO2024138000A1 (en) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024168199A1 (en) 2023-02-09 2024-08-15 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
CN121568720A (zh) 2023-07-10 2026-02-24 瑞泽恩制药公司 抗人类cacng1抗体-药物缀合物及其用途
WO2025038752A1 (en) * 2023-08-14 2025-02-20 Cancer Targeted Technology Llc Psma binding ligand-linker conjugates and methods for use thereof
TWI905962B (zh) * 2023-10-04 2025-11-21 台耀化學股份有限公司 用於綴合之化合物、綴合物及包含其之醫藥組成物
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
CN120019819A (zh) * 2023-11-17 2025-05-20 成都康弘生物科技有限公司 双毒素抗体药物偶联物及其用途
WO2025199666A1 (en) * 2024-03-25 2025-10-02 Canwell Biotech Limited Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof
WO2026032411A1 (en) * 2024-08-09 2026-02-12 Beone Guangzhou Biologics Manufacturing Co., Ltd. Self-stabilizing linker conjugates

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1572916A4 (en) 2002-04-05 2007-05-30 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005079490A2 (en) 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス, インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
AU2013222935B2 (en) * 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN105517577A (zh) * 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
KR102445502B1 (ko) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR101757977B1 (ko) 2015-06-26 2017-07-13 아주대학교산학협력단 바이오 잉크의 제조방법 및 3d 프린터 적용
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
ES3046537T3 (en) * 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
WO2018213082A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
AU2018289581C1 (en) * 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
JP7381478B2 (ja) 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド-薬物-複合体
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
SG11202010496WA (en) * 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
EA202190471A1 (ru) 2018-08-06 2021-05-24 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
IL283313B2 (en) * 2018-11-20 2025-08-01 Regeneron Pharma Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
EP3976112A1 (en) * 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
CN110974975B (zh) * 2019-12-12 2023-10-20 成都百利多特生物药业有限责任公司 一种快速释放的抗体药物偶联物
KR20220148200A (ko) 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
US20250276078A1 (en) 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
CN116897149A (zh) 2021-03-30 2023-10-17 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
BR112023019495A2 (pt) 2021-03-30 2023-11-07 Centre Nat Rech Scient Ligante de autorreação induzida por enzima tendo propriedades fisicoquímicas e farmacológicas melhoradas
GEAP202416409A (en) 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof
JP2024521629A (ja) 2021-06-02 2024-06-04 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物コンジュゲート、及びその調製方法及びその使用
WO2022262516A1 (zh) 2021-06-18 2022-12-22 北京海步医药科技有限公司 连接子及其缀合物
EP4460330A1 (en) 2022-01-06 2024-11-13 Virtuoso Binco, Inc. Conjugates, compositions and methods of use
CA3241734A1 (en) 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
CA3258612A1 (en) 2022-06-09 2023-12-14 Beigene, Ltd. Antibody drug conjugates

Similar Documents

Publication Publication Date Title
JP2023534437A5 (enExample)
JP2025502147A5 (enExample)
CN112261954B (zh) 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
JP7224365B2 (ja) 酸性自己安定化ジョイントを有する抗体薬物複合体
CN109912683B (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
JP6905941B2 (ja) キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体
JP6743015B2 (ja) Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
CN109689107B (zh) 鹅膏毒素的衍生物及其与细胞结合分子的偶联
BR112020020466A2 (pt) Conjugados de peptídeo de camptotecina
EP4313157A1 (en) Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties
EP4406606A2 (de) Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g
JP2018520130A (ja) キネシンスピンドルタンパク質(ksp)阻害剤の抗cd123抗体との抗体薬物複合体
CN106255513A (zh) 用于药物偶联物的含磺酰胺连接系统
JP2017518359A (ja) 親和性薬物コンジュゲート
JP2018525334A (ja) キネシンスピンドルタンパク質(ksp)阻害剤の抗tweakr抗体との抗体薬物複合体
AU2015386647A1 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
JPS63503144A (ja) 葉酸類縁体のアミン誘導体
CN119095625A (zh) 抗体-药物偶联物
JP2024178320A (ja) チオール多重リンカーを有するadc
CN109125736B (zh) 非天然鹅膏毒肽类抗体偶联物
CN119156232A (zh) 抗体-药物偶联物前体及其合成中间体
WO2022154116A1 (ja) 化合物またはその塩、およびそれらにより得られる抗体
CN113365969B (zh) 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
TW202412762A (zh) 奧瑞他汀衍生物及其結合物